Sort
30,917 grants matching “tumor microenvironment”
FAST-FNA immune cell profiling in HNSCC
$657,310Ralph Weissleder · Massachusetts General Hospital · R01 · FY2022 · CA
FAST-FNA immune cell profiling in HNSCC
$657,310Ralph Weissleder · Massachusetts General Hospital · R01 · FY2023 · CA
Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer
$657,258Robert H Vonderheide · University Of Pennsylvania · R01 · FY2021 · CA
Project 3: Spherical Nucleic Acids as Immunotherapeutic Agents for Prostate Cancer
$657,226Chad A. Mirkin · Northwestern University At Chicago · U54 · FY2016 · CA
Neuronal Regulation of Low-Grade Gliomagenesis
$657,214Michelle Monje-Deisseroth · Stanford University · R01 · FY2022 · CA
Targeting cellular senescence to inhibit the development and progression of ovarian endometriomas
$657,190Shannon Michelle Hawkins · Indiana University Indianapolis · R01 · FY2022 · HD
Targeting cellular senescence to inhibit the development and progression of ovarian endometriomas
$657,190Shannon Michelle Hawkins · Indiana University Indianapolis · R01 · FY2023 · HD
Remodeling the Immune Landscape in Breast Cancer Leptomeningeal Disease Using Dendritic Cell Therapy is an Effective Treatment and Protects Against Disease Recurrence.
$657,121Peter Alexander Forsyth · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA
Mechanisms of JAG1-mediated immune suppression in the pancreatic cancer microenvironment
$657,074Lan Zhou · Methodist Hospital Research Institute · R01 · FY2025 · CA
Genetically engineered mouse model to improve therapy of NUT carcinoma
$657,032Christopher A French · Brigham And Women'S Hospital · R01 · FY2025 · CA
Tumor and immune determinants of effective anti-tumor immunity in renal cell carcinoma
$656,848David Braun · Yale University · R37 · FY2023 · CA
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)
$656,816Noah M Hahn · Johns Hopkins University · R01 · FY2020 · CA
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)
$656,816Noah M Hahn · Johns Hopkins University · R01 · FY2019 · CA
Anti-CD38 targeted alpha emitter radioimmunotherapy to eliminate multiple myeloma
$656,744Damian J. Green · Fred Hutchinson Cancer Research Center · R01 · FY2018 · CA
Environmental Chemical Body Burden and Prospective Breast Cancer Risk in the Cancer Prevention Study-3 Cohort
$656,722Susan L. Neuhausen · Beckman Research Institute/City Of Hope · R01 · FY2023 · ES
A Novel Regulator of Antitumor Immunity and Immunotherapy
$656,704Rong Li · George Washington University · R01 · FY2025 · CA
Early response to radiotherapy and immunotherapy in rectal cancer: an integrated molecular, cellular, and spatial approach
$656,670Todd A Aguilera · Ut Southwestern Medical Center · R01 · FY2023 · CA
Next generation CRISPR/Cas9-RNAi mouse models for accelerated drug discovery research
$656,563Prem Khovabutr Premsrirut · Mirimus, Inc. · R44 · FY2017 · CA
Tumor Immune MicroEnvironment Facility (Scientific Core)
$656,518Wiem Lassoued · Division Of Basic Sciences - Nci · ZIC · FY2025 · CA
Targeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung Cancer
$656,426Kwok Kin Wong · New York University School Of Medicine · U01 · FY2021 · CA
Harnessing YAP-TEAD Activity as Anti-Invasion Therapeutic in Human Glioblastoma
$656,350Nadejda Mincheva Tsankova · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · NS
Notch ligands as oncogenic drivers and therapeutic targets in T-cell lymphomas
$656,250Ryan A Wilcox · University Of Michigan At Ann Arbor · R01 · FY2024 · CA
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma
$656,180Diane M Simeone · New York University School Of Medicine · R01 · FY2023 · CA
A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunity
$656,048Dung T Le · Johns Hopkins University · P01 · FY2023 · CA
Interdisciplinary Epidemiologic Consortium to Investigate T-cell Response in Colorectal Cancer
$655,962Ulrike Peters · Fred Hutchinson Cancer Center · R01 · FY2022 · CA